Unmet needs in KRAS-driven non-small cell lung cancer

0 Views

07/04/23

Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on remaining challenges in the management of KRAS G12C-mutant non-small cell lung cancer (NSCLC). Certain co-mutations such as KEAP1 have been found to worsen outcomes, and result in resistance to current therapies. Novel immunotherapies and targeted therapies are, thus, needed to treat this group of patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.